2024 ASTRO Posters and Presentations

**Scarlett Acklin-Wehnert, MD • PQA 03 • September 30 • 8-9 a.m.**
Dosimetric Outcomes with the Addition of Interstitial Needles in HDR Brachytherapy for Non-Bulky Cervical Tumor

**Mark Chen, MD, PhD • PQA 02 • September 29 • 4:45-6 p.m.**
Improving Liver SBRT Target Localization with Hybrid MRI/CBCT Technology

**Kai-Cheng Chuang, PhD, MS • PQA 09 • October 1 • 4-5 p.m.**
Multi-Channel 3D Convolutional Neural Network to Predict Grade 2 Xerostomia Following Definitive Radiation for Head and Neck Squamous Cell Carcinoma

**Junzo Chino, MD • PRO 07 • September 28 • 5:42-6:02 p.m.**
Vulvar and Cervical Cancer Treatment Updates

**Kai-Cheng Chuang, PhD, MS • PQA 09 • October 1 • 4-5 p.m.**
Multi-Channel 3D Convolutional Neural Network to Predict Grade 2 Xerostomia Following Definitive Radiation for Head and Neck Squamous Cell Carcinoma

**Christine Eyler, MD, PhD • QP 18 • October 1 • 5:15-6:15 p.m.**
Moderator: Bio 5: Genomics and Biomarkers II

**John Ginn, PhD • QP 17 • October 1 • 6:05-6:15 p.m.**
Orthogonal 2D MR Imaging and Manifold Learning Enables Real-Time 3D Tumor Tracking

**Alex Gooding, MD, PhD • PQA 06 • September 30 • 5-6 p.m.**
Unbiased Functional Genomics Screen Identifies Unique Therapeutic Vulnerabilities in Osimertinib-Resistant NSCLCs

**Emily Harris, MD • PQA 03 • September 30 • 8-9 a.m.**
Local Recurrence Rates following Equivocal 3-month Post-Treatment PET after High Dose Rate Brachytherapy for Locally Advanced Cervical Cancer: An Updated Cohort
Christina Huang, MD, MS • SS 27 • September 30 • 5-5:10 p.m.
Long-Term Update of a Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma

Abhishek Kumar, MD, MAS • PQA 08 • October 1 • 2:30-3:45 p.m.
Association of MRI Capsular Involvement and Extraprostatic Extension on Metastasis Free and Overall Survival in Localized Prostate Cancer Treated with Radiation

Dominic LaBella, MD • PQA 08 • October 1 • 2:30-3:45 p.m.
Efficacy of Oligometastasis Directed Stereotactic Body Radiation Therapy in De Novo Oligometastatic Prostate Cancer

Efficacy of Oligorecurrence Directed Stereotactic Body Radiation Therapy in Oligorecurrent Prostate Cancer

Nicole Larrier, MD, MS • SS 13 • September 30 • 8-9 a.m.
Moderator: Peds 1: Functional Outcomes and Disease Control Following Multimodality Therapy in Pediatric Oncology

Xinyi Li, PhD • PQA 02 • September 29 • 4:45-6 p.m.
Control Dosimetric Outcome of AI-Generated Plans through OAR Prioritization for Head-and-Neck Cancer: An Investigation on Input Sensitivity

Jim Leng, MD • PQA 10 • October 2 • 10:30-11:45 a.m.
Cost Estimates of Brachytherapy Delivery in Northern Tanzania Using Time-Driven Activity Based Costing

Susan McDuff, MD, PhD • SS 31 • October 1 • 12:45-2 p.m.
Moderator: Breast Cancer 3: Toxicity

Trey Mullikin, MD • PQA 08 • October 1 • 2:30-3:45 p.m.
Comparison of Local Medicare Guidance and Medicare Advantage Plans for Stereotactic Radiosurgery for Brain Metastases

Manisha Palta, MD • EDU 50 • October 1 • 4:32-4:47 p.m.
Finding Clarity in the “Black-Box” of AI and Integration into Clinical Care